Litcius/Paper detail

Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study

Emmanuel Gonzalès, Winita Hardikar, Michael Stormon, Alastair Baker, Loreto Hierro, Dorota Gliwicz, Florence Lacaille, Alain Lachaux, Ekkehard Sturm, Kenneth D.R. Setchell, Ciara Kennedy, Alejandro Dorenbaum, Jana I. Steinmetz, Nirav K. Desai, Andrew J Wardle, Will Garner, Pamela Vig, Thomas Jaecklin, Étienne Sokal, Emmanuel Jacquemin

2021The Lancet170 citationsDOIOpen Access PDF

Topics & Concepts

Alagille syndromeMedicinePlaceboCholestasisClinical endpointPopulationInternal medicineGastroenterologyAdverse effectBile acidRandomized controlled trialPediatricsPathologyEnvironmental healthAlternative medicinePediatric Hepatobiliary Diseases and TreatmentsDrug Transport and Resistance MechanismsGallbladder and Bile Duct Disorders
Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study | Litcius